Mark Bachleda - 08 Oct 2021 Form 4 Insider Report for Galera Therapeutics, Inc. (GRTX)

Reporting relationship: Chief Commercial Officer
Issuer ticker: GRTX
Reported as of: 08 Oct 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Oct 2021, 20:23:52 UTC
Next SEC filing: 02 Mar 2022
Source filing: View source filing
Reporting owner signature: /s/ J. Mel Sorensen, Attorney-in-Fact for Mark J. Bachleda

Key filing fact

Mark Bachleda filed Form 4 for Galera Therapeutics, Inc. (GRTX) on 12 Oct 2021.

Key facts

This page summarizes Mark Bachleda's Form 4 filing for Galera Therapeutics, Inc. (GRTX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 12 Oct 2021, 20:23.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GRTX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +200,000
Change %
Price: $0.000000
Shares after: 200,000
Date: 08 Oct 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 200,000
Exercise price: $7.84
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests and becomes exercisable as to 25% on October 8, 2022, and in thirty-six (36) substantially equal monthly installments over a three year period thereafter.